@article{TP153037,
author = {Chunlei Chen and Bing Hu and Enmei Liu and Jinhai Ma and Changshan Liu and Xiaoyan Dong and Huifen Zi and Chuangli Hao and Rongjun Lin and Xiangrong Zheng and Bingfei Li and Fenhua Chen and Mei Fang and Weimin Tian and Zhiqiang Zhuo and Deyu Zhao and Zhimin Chen and Yuejie Zheng and Jingyang Zheng and Yong Yin and Qiuyu Tang and Liqun Wu and Li Gu and Jinzhun Wu and Liyi He and Tao Ai and Hanmin Liu and Zhiying Han and Yunbo Mo and Zhiliang Tian and Quan Lu and Yingxue Zou},
title = {Ambroxol hydrochloride and clenbuterol hydrochloride oral solution versus ambroxol hydrochloride injection for pediatric lower respiratory tract infection with mucoid sputum: a multicenter, non-randomized observational study in China},
journal = {Translational Pediatrics},
volume = {15},
number = {4},
year = {2026},
keywords = {},
abstract = {Mucoid sputum is common in pediatric patients with lower respiratory tract infection (LRTI) and can exacerbate cough, contribute to difficulty in expectoration and dyspnea, and even cause suffocation. Although ambroxol hydrochloride and clenbuterol hydrochloride oral solution [AHCHOS (or Yitanjing)] is widely used in pediatric practice, high-quality real-world evidence comparing it with conventional expectorant therapies such as ambroxol hydrochloride injection (AHI) remains limited. This study aimed to investigate the efficacy and safety of AHCHOS in pediatric patients with LRTI complicated with mucoid sputum.},
issn = {2224-4344}, url = {https://tp.amegroups.org/article/view/153037}
}